The molecular history of IDH-mutant astrocytomas without adjuvant treatment.
Ontology highlight
ABSTRACT: Hypermutation and malignant transformation are potential complications arising from temozolomide treatment of IDH-mutant gliomas. However, the natural history of IDH-mutant low-grade gliomas without temozolomide treatment is actually under-studied. We retrieved retrospectively from our hospitals paired tumors from 19 patients with IDH-mutant, 1p19q non-codeleted Grade 2 astrocytomas where no interim adjuvant treatment with either temozolomide or radiotherapy was given between primary resections and first recurrences. Tissues from multiple recurrences were available from two patients and radiotherapy but not temozolomide was given before the last specimens were resected. We studied the natural molecular history of these low-grade IDH-mutant astrocytomas without pressure of temozolomide with
SUBMITTER: Shi ZF
PROVIDER: S-EPMC11835445 | biostudies-literature | 2025 Mar
REPOSITORIES: biostudies-literature
ACCESS DATA